The effect of metabolic dysfunction-associated steatotic liver disease on the disease progression in patients with COVID-19 associated pneumonia
Authors:
- Taisiia TurankovaTTTaisiia Turankova
- Philipp RoshchinPRPhilipp Roshchin
- Dina BaimukhambetovaDBDina Baimukhambetova
- Oleg MestnikovOMOleg Mestnikov
- Nadezhda MorozNMNadezhda Moroz
- Daria VarganovaDVDaria Varganova
- Marianna SemenistaiaMSMarianna Semenistaia
- Alexey BrazhnikovABAlexey Brazhnikov
- Chavdar PavlovCPChavdar Pavlov
Open Access
- 1 October 2025
- journal article
- Published by AME Publishing Company in Translational Gastroenterology and Hepatology
- Vol. 10, 64
Abstract
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a common form of chronic liver disease, found in more than a quarter of the world’s population. People with MASLD are at a high risk of acquiring severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The risk of a mild cold turning into severe pneumonia is also high. The aim of our study was to evaluate the effect of MASLD as a risk factor for the severity of coronavirus disease-associated pneumonia (COVID-AP). Methods: Our prospective, Russian cohort study included 100 adults (≥18 years old), of any sex, with COVID-AP. The SARS-CoV-2 infection was confirmed on nucleic acid amplification or using the SARS-CoV-2 antigen tests. Any possible secondary causes of liver steatosis were excluded, and alcohol consumption was assessed. The presence of significant hepatic steatosis (more than 30%) was estimated from computed tomography (CT) results. Results: Based on the presence of significant steatosis, in combination with other metabolic factors, two groups were formed: 25 patients with MASLD and 74 patients without significant steatosis, serving as controls. One patient was excluded from the MASLD group due to alcohol abuse. The two groups were comparable by sex (P=0.58) and age (P=0.96). Body mass index (BMI) (PConclusions: Liver steatosis, regardless of other metabolic risk factors, increased the need for biological therapy, whereas the need for antibiotic therapy was a consequence of T2DM. Our study showed a more severe course of COVID-AP in people with MASLD and higher mortality.Keywords
This publication has 30 references indexed in Scilit:
- A meta-analysis of comorbidities in COVID-19: Which diseases increase the susceptibility of SARS-CoV-2 infection?Computers in Biology and Medicine, 2021
- High prevalence for obesity in severe COVID-19: Possible links and perspectives towards patient stratificationBiochimie, 2020
- Nonalcoholic fatty liver disease is associated with COVID-19 severity independently of metabolic syndrome: a retrospective case-control studyEuropean Journal of Gastroenterology & Hepatology, 2020
- Non-alcoholic fatty liver diseases in patients with COVID-19: A retrospective studyJournal of Hepatology, 2020
- Higher frequency of hepatic steatosis at CT among COVID-19-positive patientsAbdominal Radiology, 2020
- Metabolic‐associated fatty liver disease is associated with severity of COVID‐19Liver International, 2020
- Risk of severe illness from COVID-19 in patients with metabolic dysfunction-associated fatty liver disease and increased fibrosis scoresGut, 2020
- Global burden of NAFLD and NASH: trends, predictions, risk factors and preventionNature Reviews Gastroenterology & Hepatology, 2017
- Noninvasive assessment of macrovesicular liver steatosis in cadaveric donors based on computed tomography liver‐to‐spleen attenuation ratioLiver Transplantation, 2015
- Detection of Hepatic Steatosis on Contrast-Enhanced CT Images: Diagnostic Accuracy of Identification of Areas of Presumed Focal Fatty SparingAmerican Journal of Roentgenology, 2012